I do it, but I decide with whom

Social interactions and communication shape the desires and preferences of men and women. While it is true that some men have modified their behavior due to feminist women, the same happened with some women, who changed attraction patterns thanks to new alternative masculinities (NAM). This study examines the latter, focusing on social interactions mediated by language, as a crucial element to impact and change the desires of people. For this purpose, six autobiographical interviews were conducted with women aged 19-39 years, from two different countries and continents, paying attention to the narratives of their sexual-affective relationships. Using the communicative methodology, interactions have been analyzed from verbal communication and nonverbal communication, based on the consequences of the actions rather than intentionality. The results of this study show how dialogic communicative acts with NAMs influenced some women who first defended or justified actions of male perpetrators to later prefer to support female survivors against their perpetrators. Analysis reveals that communicative acts grounded in such language that enacted the desire of NAM for women of solidarity have shaped some memories of women of relationships with dominant traditional masculinities (DTM) and, ultimately, contributed to change their attraction and election patterns

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease:a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1-3 at initiation of treatment with evidence of rapidly progressing disease. In this paper, on behalf of the ERA-EDTA Working Groups of Inherited Kidney Disorders and European Renal Best Practice, we aim to provide guidance for making the decision as to which ADPKD patients to treat with tolvaptan. The present position statement includes a series of recommendations resulting in a hierarchical decision algorithm that encompasses a sequence of risk-factor assessments in a descending order of reliability. By examining the best-validated markers first, we aim to identify ADPKD patients who have documented rapid disease progression or are likely to have rapid disease progression. We believe that this procedure offers the best opportunity to select patients who are most likely to benefit from tolvaptan, thus improving the benefit-to-risk ratio and cost-effectiveness of this treatment. It is important to emphasize that the decision to initiate treatment requires the consideration of many factors besides eligibility, such as contraindications, potential adverse events, as well as patient motivation and lifestyle factors, and requires shared decision-making with the patient.</p

Procedimiento para la protección y estabilización del color de carnes y productos elaborados de carne, frescos, marinados o parcialmente deshidratados, tratados por alta presión

Procedimiento para la protección y estabilización del color de carnes y productos elaborados de carne, frescos, marinados o parcialmente deshidratados, tratados por alta presión. La pérdida de color original de la carne es un problema en la aplicación de altas presiones, debido a un aumento de la luminosidad y un descenso de la intensidad de la tonalidad roja, que pasa a rosada o marrón, reduciendo su aceptación. Este invento mantiene el color natural de carnes frescas, y sus productos elaborados, ahumados, adobados, marinados, salados, parcialmente deshidratados o reconstituidos previamente a la presurización. El tratamiento de presión debe evitar la descongelación del producto, o al menos, que la temperatura del producto sobrepase los 0&ORDM; C en ningún momento. También se evitarían otros procesos físico-químicos tendentes a la recuperación del color original que pudieran producir cambios en la composición deseada del producto o el rechazo del consumidor

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease : a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1-3 at initiation of treatment with evidence of rapidly progressing disease. In this paper, on behalf of the ERA-EDTA Working Groups of Inherited Kidney Disorders and European Renal Best Practice, we aim to provide guidance for making the decision as to which ADPKD patients to treat with tolvaptan. The present position statement includes a series of recommendations resulting in a hierarchical decision algorithm that encompasses a sequence of risk-factor assessments in a descending order of reliability. By examining the best-validated markers first, we aim to identify ADPKD patients who have documented rapid disease progression or are likely to have rapid disease progression. We believe that this procedure offers the best opportunity to select patients who are most likely to benefit from tolvaptan, thus improving the benefit-to-risk ratio and cost-effectiveness of this treatment. It is important to emphasize that the decision to initiate treatment requires the consideration of many factors besides eligibility, such as contraindications, potential adverse events, as well as patient motivation and lifestyle factors, and requires shared decision-making with the patient